JAK2 and essential thrombocythemia: Conditional knock-in mice expressing either the murine or human mutant protein under control of the endogenous JAK2 promoter also showed phenotypic variability: heterozygous and homozygous mice expressing murine JAK2 V617F developed PV, while mice heterozygous for human JAK2 V617F developed ET-like symptoms [27–30].